GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rigel Pharmaceuticals Inc (NAS:RIGL) » Definitions » PS Ratio

Rigel Pharmaceuticals (Rigel Pharmaceuticals) PS Ratio

: 1.65 (As of Today)
View and export this data going back to 2000. Start your Free Trial

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Rigel Pharmaceuticals's share price is $1.11. Rigel Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.67. Hence, Rigel Pharmaceuticals's PS Ratio for today is 1.65.

The historical rank and industry rank for Rigel Pharmaceuticals's PS Ratio or its related term are showing as below:

RIGL' s PS Ratio Range Over the Past 10 Years
Min: 0.96   Med: 7.48   Max: 580
Current: 1.64

During the past 13 years, Rigel Pharmaceuticals's highest PS Ratio was 580.00. The lowest was 0.96. And the median was 7.48.

RIGL's PS Ratio is ranked better than
86.17% of 998 companies
in the Biotechnology industry
Industry Median: 9.06 vs RIGL: 1.64

Rigel Pharmaceuticals's Revenue per Sharefor the three months ended in Dec. 2023 was $0.21. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.67.

Warning Sign:

Rigel Pharmaceuticals Inc revenue per share is in decline over the past 12 months.

During the past 12 months, the average Revenue per Share Growth Rate of Rigel Pharmaceuticals was -3.60% per year. During the past 3 years, the average Revenue per Share Growth Rate was 1.40% per year. During the past 5 years, the average Revenue per Share Growth Rate was 21.30% per year. During the past 10 years, the average Revenue per Share Growth Rate was 26.60% per year.

During the past 13 years, Rigel Pharmaceuticals's highest 3-Year average Revenue per Share Growth Rate was 164.00% per year. The lowest was -76.20% per year. And the median was 9.60% per year.

Back to Basics: PS Ratio


Rigel Pharmaceuticals PS Ratio Historical Data

The historical data trend for Rigel Pharmaceuticals's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rigel Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PS Ratio
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.05 5.43 3.03 2.15 2.16

Rigel Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PS Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.15 1.76 1.76 1.42 2.16

Competitive Comparison

For the Biotechnology subindustry, Rigel Pharmaceuticals's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rigel Pharmaceuticals PS Ratio Distribution

For the Biotechnology industry and Healthcare sector, Rigel Pharmaceuticals's PS Ratio distribution charts can be found below:

* The bar in red indicates where Rigel Pharmaceuticals's PS Ratio falls into.



Rigel Pharmaceuticals PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Rigel Pharmaceuticals's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=1.11/0.671
=1.65

Rigel Pharmaceuticals's Share Price of today is $1.11.
Rigel Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.67.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Rigel Pharmaceuticals  (NAS:RIGL) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Rigel Pharmaceuticals PS Ratio Related Terms

Thank you for viewing the detailed overview of Rigel Pharmaceuticals's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Rigel Pharmaceuticals (Rigel Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
611 Gateway Boulevard, Suite 900, South San Francisco, CA, USA, 94080
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility to develop and market the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
Executives
Raul R Rodriguez officer: Sr VP of Bus Dev and Com Ops 1180 VETERANS BOULEVARD, SOUTH SAN FRANCISCO CA 94080
David A Santos officer: EVP, Chief Commercial Officer RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD., SOUTH SAN FRANCISCO CA 94080
Wolfgang Dummer officer: EVP & CMO 5491 OPTICAL CT., SAN JOSE CA 95138
Dean L Schorno officer: EVP & Chief Financial Officer 301 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Raymond J. Furey officer: EVP, GC & Corp Sec 1300 N. KELLOGG DRIVE, SUITE D, ANAHEIM CA 92807
Alison L. Hannah director 12701 COMMONWEALTH DRIVE, SUITE 9, FORT MYERS FL 33913
Gary A Lyons director 12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130
Anthony Gregg Lapointe director PO BOX 83216, GAITHERSBURG MD 20883-3216
Brian L. Kotzin director RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BOULEVARD, SOUTH SAN FRANCISCO CA 94060
Kamil Ali-jackson director C/O ACLARIS THERAPEUTICS, INC., 101 LINDENWOOD DRIVE, SUITE 400, MALVERN PA 19355
Jane Wasman director C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Nelson Cabatuan officer: Principal Accounting Officer RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD., SOUTH SAN FRANCISCO CA 94080
Anne-marie Duliege officer: Chief Medical Officer 4001 MIRANDA AVENUE, PALO ALTO CA 94304
Mayer Eldon C. Iii officer: EVP & Chief Commercial Officer RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD., SOUTH SAN FRANCISCO CA 94080
Stacy Markel officer: EVP Human Resources RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080